Previous reports show increased incidence of venous thromboembolism [VTE, deep-vein thrombosis (DVT) and pulmonary embolus (PE)] in sickle cell disease (SCD) patients but did not account for frequency of hospitalization. We determined the incidence of VTE in a SCD cohort versus matched controls. For SCD patients, risk factors for incident VTE, recurrence and the impact on mortality were also determined. Among 6237 patients with SCD, 696 patients (11Á2%) developed incident-VTE: 358 (51Á6%) had PE (AEDVT); 179 (25Á7%) had lower-extremity DVT only and 158 (22Á7%) had upper-extremity DVT. By 40 years of age, the cumulative incidence of VTE was 17Á1% for severe SCD patients (hospitalized ≥3 times a year) versus 8Á0% for the matched asthma controls. Amongst SCD patients, women (Hazard ratio [HR] = 1Á22; 95% confidence interval [CI]: 1Á05-1Á43) and those with severe disease (HR = 2Á86; 95% CI: 2Á42-3Á37) had an increased risk of VTE. Five-year recurrence was 36Á8% in patients with severe SCD. VTE was associated with increased risk of death (HR = 2Á88, 95% CI: 2Á35-3Á52). In this population-based study, the incidence of VTE was higher in SCD patients than matched controls and was associated with increased mortality. The high incidence of recurrent VTE in patients with severe SCD suggests that extended anticoagulation may be indicated.
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Sickle cell disease (SCD) is an inherited red blood cell disorder that commonly affects people whose ancestors are from sub-Saharan Africa, Spanish-speaking regions in the Western Hemisphere, Saudi Arabia, India and Mediterranean countries. The genetic variants of SCD include homozygous SS, heterozygous SC and S-b thalassemia. In the United States, approximately 72 000-100 000 people, mostly of African ancestry, are affected by this condition (Hassell, 2010) .
The complications of SCD are varied. Vascular occlusion with ischaemia-reperfusion injury is thought to underlie many, if not all, of these complications. The sickle mutation is also associated with increased risk of venous thromboembolism [VTE: deep-vein thrombosis (DVT) and/or pulmonary embolism (PE)]. In a case-control study, sickle cell trait was associated with a nearly 2-fold increased risk of VTE and a nearly 4-fold increased risk of PE (Austin et al, 2007) . A study of the United States National Hospital Discharge Survey reported that the overall prevalence of PE was approximately 4 times higher in SCD patients compared to African Americans without SCD (0Á44% vs. 0Á12% respectively) (Stein et al, 2006) and a case-control study of inpatients in Pennsylvania reported a prevalence of inpatient PE that was 50-to 100-fold higher in the SCD population compared to the general hospitalized population (Novelli et al, 2012) .
In a single-institution cohort study of 404 patients with SCD, the prevalence of VTE was 25% (Naik et al, 2013) and the same group reported a cumulative incidence of 11Á3% by the age 40 years in a retrospective analysis of patients ≥15 years of age (Naik et al, 2014) . In contrast, only 2 of 1063 children <12 years of age from a Brazilian SCD cohort had DVT and both were associated with a central venous catheter (Boechat Tde et al, 2015) . Those with the less common genotypes of SCD also appear to have increased risk of VTE. In an analysis of 85 patients with haemoglobin (Hb) SC disease and 31 with S/b + thalassaemia, 32 (28%) patients had a history of non-catheter related VTE (Yu et al, 2016) . While the increased risk of VTE in the SCD population seems well established, SCD patients are frequently hospitalized and hospitalization is a risk factor for VTE (White, 2003) . The risk of VTE in SCD patients over and above that associated with hospitalization has not been well described, nor has the average yearly frequency of hospitalization (a measure of disease severity) been analysed as a risk factor for VTE. Finally, data is sparse regarding the incidence and time-course of recurrent VTE in SCD patients, and whether there is an association between VTE and mortality. To address these important questions, we initiated a large, population-based cohort study of SCD patients with up to 23 years of follow-up.
Methods

Database
This was a retrospective cohort study. The State of California Office of Statewide Health Planning and Development (OSHPD) maintain records of all patients hospitalized in non-federal hospitals in the state, called the Patient Discharge Database (PDD). Since July 1990, the State of California has required that these hospitals report up to 25 diagnoses and up to 20 procedures associated with each hospitalization, coded using the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM; National Center for Health Statistics 2014). Since 2005, an Emergency Department Utilization (EDU) database of all hospital associated EDU facilities has also been mandated and a presenton-admission (POA) indicator has been required for essentially all PDD diagnoses since 1996. In addition to diagnostic and procedure information, demographic information, including age, gender, race/ethnicity, insurance coverage, type of admission and disposition, is collected in both PDD and EDU. An encrypted form of the social security number, called the record linkage number (RLN), is used to identify unique individuals, allowing serial linking of multiple hospitalization records over time. The~5% of patients who did not have a RLN were excluded from this analysis. This administrative database did not contain laboratory or medication information. All data was linked to the California master death registry providing death information through 2011. This study was approved by the California Health and Human Services Agency Committee for the Protection of Human Subjects, and the University of California, Davis Institutional Review Boards.
Patient identification
Sickle cell disease patients were identified using search algorithms informed by the Registry and Surveillance System for Haemoglobinopathies (RuSH) project and validated by the Public Health Research, Surveillance and Epidemiology in Hemoglobinopathies (PHRESH) study (Paulukonis et al, 2014) . To be included in this analysis, cases had to have: (i) at least 2 separate admissions with an SCD code in the principal (first position) diagnosis, or (ii) at least one admission with an SCD code in the principal position and a SCD code in a secondary position in at least 2 additional admissions. Specific SCD ICD-9-CM codes (282Á41, 282Á42, 282Á60, 282Á61, 282Á62, 282Á63, 282Á64, 282Á68, 282Á69) were used. In our cohort, 63% and 37% of all inpatient hospitalizations and emergency department visits, respectively, had a principal diagnosis of SCD. A random sample of discharge records, representing 10% of the entire derived cohort, was reviewed by the senior author to determine face validity. Although, genotype is available by ICD-9-CM codes, 67% had multiple genotypes coded across different admissions, therefore genotype was deemed unreliable. Patients ≥65 years of age at first encounter were particularly unlikely to have SCD based on the review of accompanying diagnoses from serial admissions; therefore, all patients had to be <65 years of age at first encounter to be considered SCD cases. Thus, the algorithm emphasized specificity over sensitivity.
Covariates
Patient sex and race/ethnicity were obtained from the patients' first encounter. Birth year was calculated using the age at first admission. Birth year was then categorized into 10-year birth cohorts (<1940, 1940-1949, 1950-1959, 1960-1969, 1970-1979, 1980-1989, 1990-1999, 2000-2009, 2010-2013) . SCD severity was dichotomized to severe SCD and less severe SCD. Patients who averaged ≥3 admissions (PDD and EDU combined) per year were defined as severe SCD patients, while all other patients were defined as less severe. SCD severity classification was based on previously published data showing greater mortality in SCD patients with ≥3 hospitalizations per year (Platt et al, 1991) , and criterion that was later used as one of the indications for starting hydroxycarbamide (also termed hydroxyurea) treatment in the Multicenter Study of Hydroxyurea in Sickle Cell Anemia study (Charache et al, 1995) . To determine the percentage of SCD patients that bleed within 1 year of VTE, major bleeding was identified using Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study-identified set of ICD-9-CM codes (Singer et al, 2009; Fang et al, 2011) . Cases were classified as having intra-cranial bleeding, gastrointestinal bleeding or other major bleeding.
Outcomes
The primary outcome was the incidence of first acute VTE (PE, DVT or upper extremity DVT). We identified VTE cases using the highly specific ICD-9-CM codes shown in Table S1 ( White et al, 2010) . To be defined as acute VTE, a PE or DVT, the code had to be in the principle or second diagnosis position during a PDD hospitalization or an emergency department visit. In order to capture VTE as a complication of a procedure, we also included patients with a principal diagnosis code of 997Á2 or 997Á3 plus the corresponding DVT or PE in the second position. An upper extremity (UE) code was allowed in any of the 25 diagnosis codes.
Statistical methods
Univariate descriptive statistics using chi-squared test were used to describe characteristics of the cohort. The competing-risk cumulative incidence of acute VTE and the person-time rate of acute VTE (per 1000 patient-years) were calculated. In order to determine the incidence of acute VTE for patients with SCD versus hospitalized asthma controls, conditional competing-risk cumulative incidence was calculated among African-Americans: using a greedy match algorithm, each SCD case was matched to 3 African-American asthma controls for gender, age at entry into the SCD cohort (AE2 years), year of admission (AE2 years), and hospital frequency (averaged ≥3 admissions per year or averaged <3 admissions per year). Asthma patients were selected as comparators because asthma is prevalent in African-Americans across the lifespan (Bhan et al, 2015) , may require frequent hospitalization, and is associated with increased VTE (Majoor et al, 2013) . Trauma admissions were excluded from eligible controls.
Cox proportional hazards regression was used to analyse potential risk factors associated with incident VTE within the SCD cohort. To determine the association of VTE with mortality from all causes in the SCD cohort, we used Cox proportional hazard regression with incident and recurrent VTE entered as a time dependent covariates. We calculated recurrence rates of VTE, defined as another acute VTE admission at least 14 days after the incident VTE discharge date. Cumulative incidence and all Cox proportional hazard regression models were computed using age as the time scale. Regression models were stratified by birth cohort to adjust for diagnosis and treatment changes of VTE over the study period. All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).
Results
There were 6237 SCD patients identified (Fig 1; Table I ) with a median follow-up of 15 years. In this SCD cohort, 696 patients (11Á2%) developed an incident acute VTE. Three hundred and fifty-nine (51Á6%) were PE (AEDVT) and 158 (22Á7%) were upper extremity only. Overall, 51Á9% and 60Á0% of the VTE events occurred ≤60 and ≤90 days of a prior inpatient hospital discharge, respectively. Of the patients with VTE and antecedent inpatient admission within 90 days of hospital discharge, 94% had a length-of-stay (LOS) ≥3 days. Similarly, 92Á7% had a LOS ≥3 days when the event occurred within 60 days of a hospital discharge. Therefore, the majority of these events would be considered provoked VTE by a transient risk factor using a recent consensus guideline (Kearon et al, 2016a) . At age 40 years, the cumulative incidence of VTE among all SCD patients was 12Á5% (95% confidence interval [CI], 11Á5-13Á6). The overall incidence density rate of incident VTE was 8Á4 per 1000 patient-years, but this varied by SCD severity, with an incidence of 14Á0 per 1000 patient-years among the severe SCD patients and 4Á6 per 1000 patient-years among those patients with less severe SCD. The median age of patients with incident VTE was 31 years. Eighteen of 414 (4Á3%) women with VTE had a pregnancy code at the time of or within 6 weeks prior to their thrombotic event. Of the 158 patients with upper extremity thrombosis, 65 (41Á1%) had a central venous catheter placed prior to the VTE. Three per cent (N = 20) of the SCD patients with VTE experienced a major bleed less than 1 year after their VTE event (intracranial haemorrhage, N = 3; gastro-intestinal bleeds, N = 15; other major bleeds, N = 2). Figure 2 shows the conditional cumulative incidence of VTE adjusted for the competing risk of death among African-American SCD patients and their matched asthma controls by disease severity/average hospitalizations. At 40 years of age, the cumulative incidence of VTE was highest among severe SCD patients at 17Á1% (95% CI, 15Á2-19Á2); followed by frequently hospitalized asthma patients at 8Á0% (95% CI, 7Á1-9Á1); less severe SCD patients at 6Á8% (95% CI, 5Á7%-8Á0) and less frequently hospitalized asthma patients at 1Á6% (95% CI, 1Á3-2Á0) (Gray's equality test P < 0Á0001). In a sensitivity analysis excluding patients with UE thrombosis (125 SCD patients and 130 asthma patients), the cumulative incidence at 40 years was 13Á2% (95% CI, 11Á4-15Á0) in severe SCD patients and 6Á7% (95% CI, 5Á7-7Á7) in frequently hospitalized asthma patients.
A multivariate regression analysis was performed within the SCD cohort to consider risk factors for incident VTE (Table II) . Severe SCD was associated with a nearly threefold increased risk of incident VTE (Hazard ratio [HR] = 2Á86, 95% CI, 2Á42-3Á37). Female sex was associated with a 22% increased risk (HR = 1Á22, 95% CI, 1Á05-1Á43). Because the risk of VTE is increased in women during pregnancy or within the post-partum period, we conducted a sensitivity analysis excluding women with a pregnancy VTE code or a pregnancy code within 6 weeks prior to the incident VTE (n = 18, 4Á3%); in these analyses, women still had an increased risk of VTE (HR = 1Á18, 95% CI, 1Á01-1Á38).
A total of 232 recurrent VTE events occurred following an incident VTE event, with a median time to recurrence of 359 days. The overall cumulative incidence of recurrent VTE was 23Á6% at 2-years and 31Á3% at 5-years (data not shown in Figures) . Recurrence was greater in those with severe SCD [2 year incidence = 29Á1% (95% CI, 25Á0-33Á4); 5 year incidence = 36Á8% (95% CI, 32Á2-41Á5)] than for those with less severe disease [2 year incidence = 12Á1% (95% CI, 8Á1-16Á8); 5 year incidence = 19Á6% (95% CI, 14Á4-25Á4)] (Fig 3) .
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Multivariate regression analyses were used to determine the effect of VTE and recurrent VTE on mortality of all causes among SCD patients. The median age of death of SCD patients was 40 years (range 1-82). Severe disease was associated with increased mortality (HR = 1Á83, 95% CI, 1Á61-2Á09). Those who developed incident VTE had a nearly three-fold increased risk of death compared to SCD patients without incident VTE (HR = 2Á88, 95% CI, 2Á35-3Á52). All VTE types were associated with higher mortality (Table III) . Recurrent VTE was not associated with a higher risk of death compared to SCD patients who had an incident, but no recurrent VTE (HR = 0Á97, 95% CI, 0Á69-1Á38).
Discussion
In our large study of California patients with SCD, we observed that patients with SCD have an increased risk of VTE independent of frequency of hospitalization. SCD patients had a 2-to 4-fold increased risk of VTE compared to asthma patients matched on a number of factors, including average yearly hospitalizations. Within the SCD cohort, women and those with severe disease had a higher risk of VTE. The development of VTE, regardless of type, was associated with over 2-fold increased mortality, even when accounting for disease severity. In addition, recurrent VTE was common in patients with severe SCD, occurring in 36Á8% of these patients at 5 years, but was not associated with a further increased risk of mortality compared to incident VTE only.
Previous reports of increased VTE incidence in SCD patients did not account for hospitalizations. Because frequent hospitalization alone might increase the overall rate of VTE in SCD patients, we determined the cumulative incidence of VTE in African-American SCD patients compared to African-American asthma controls by frequency of hospitalizations and found that severe and less severe SCD patients had a higher incidence of VTE than frequently and less frequently hospitalized asthma controls, respectively. However, 40% of incident VTE events occurred >90 days following a hospital discharge and thus do not meet the widely accepted criteria for having a "provoked VTE by hospitalization"; we advocate that nearly all VTE in patients with SCD are also "provoked by a persistent risk factor" (Kearon et al, 2016a) , and warrants consideration for indefinite anticoagulation. The median age of SCD patients at the time of the incident VTE event was 31 years, which is considerably younger than the median age of patients with VTE in the general population (White, 2003; Heit, 2006 Heit, , 2015 . Together, these findings suggest that patients with SCD have an increased risk of VTE that is independent of frequent hospitalization. Our findings corroborate but also extend on the reports of previous investigators. Using the National Discharge Survey, Stein et al (2006) reported that in patients < age 40 years, 0Á44% of those with SCD had a discharge diagnosis of PE compared with 0Á12% of African Americans without SCD. However, the prevalence of DVT was similar in SCD patients (0Á44%) and African Americans without SCD (0Á40%). Novelli et al (2012) used similar administrative discharge data to estimate the incidence of PE amongst SCD patients. The incidence of PE was higher in the SCD population than in the non-SCD population by 50-to 100-fold, although this incidence figure was based on a SCD DVT, Deep Vein Thrombosis; LE, lower extremity; NOS, not otherwise specified; PE, Pulmonary Embolism; SCD, sickle cell disease.
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ª 2017 John Wiley & Sons Ltd population estimate and not derived through analysis of the database itself. This study also included those with a sickle cell trait code and did not track individual patients, thus cumulative incidence and recurrent PE data could not be generated. We found a two-fold increased risk of VTE among severe SCD patients compared to frequently hospitalized matched African-American asthma patients and a fourfold increased risk of VTE among less severe SCD patients compared to less frequently hospitalized matched asthma patients. As asthma is also associated with increased risk of VTE (Majoor et al, 2013) , our findings probably underestimate the magnitude of increased VTE risk among SCD patients compared to the general population. In a sub-group analysis of The Cooperative Study of Sickle Cell Disease (1523 patients age ≥15 years at entry followed between 1978 to 1988), the incidence rate for first VTE was 5Á2 events/1000 person-years and the cumulative incidence of VTE was 11Á3% by age 40 years (Naik et al, 2014) ; these findings are very similar to the 12Á5% seen in the present study. Individuals with the SS or Sb 0 -thalassemia genotype had the highest rate of VTE (7Á6 events/1000 person-years) (Naik et al, 2013) . SCD patients with VTE were observed to have an over 2-fold increased risk of mortality, consistent with the findings from our study that adjusted for SCD disease severity. In our study, the increased mortality was evident regardless of the type of VTE, even upper extremity thrombosis. Whether this is due to complications of VTE or because VTE is a clinical biomarker for more severe disease cannot be determined. Additionally, we showed that recurrent VTE was not associated with increased mortality compared to incident VTE without recurrence. The present study found that women with SCD were at greater risk for development of VTE, even after adjustment for other predictive factors. This is in contrast to the general population, where male sex is usually found to be associated with higher rates of VTE (White, 2003; Heit, 2006) . Pregnancy did not explain the increased risk in our study. It is possible that many women were on oestrogen-containing oral contraceptive agents, but these data were not available. One possibility is a unique interaction between the marked inflammatory and hypercoagulable environment in women with SCD.
More recently, in a single-institution, cross-sectional study of 404 SCD patients, 104 patients (25%) had a history of VTE, with a median age at diagnosis of 29Á9 years (Naik et al, 2013) . Non-catheter-related VTE was found in 18Á8% of SCD patients. Sickle variant genotypes (such as Hb SC) conferred a nearly two-fold higher risk of non-catheterrelated VTE compared with sickle cell anaemia genotypes (SS/Sb 0 ) (Naik et al, 2013) . Yu et al (2016) also reported a high incidence of VTE in patients with the less common SCD genotypes. With a median follow-up of 4Á8 years (range 0-34 years) after initial VTE, 25 patients (24Á8%) had a documented recurrence; the median time to recurrence was 1Á8 years (range 0Á1-12 years). In the present study, we found the overall 5-year cumulative incidence of recurrence to be higher (31Á2%) than in these prior studies and the median time to recurrence to be shorter (about 1 year). Thirty patients (7Á4%) in the cohort studied by Naik et al (2013) died during the study period. Adjusting for covariates, non-catheter-related VTE was associated with an over threefold increased risk of death (relative risk of 3Á63), similar to the hazard for death (HR = 2Á88) found in our study. The cumulative incidence of recurrent events found in this study is consistent with the rate reported in men with unprovoked VTE (~30% at 5 years) (Kearon et al, 2015) , indicating that SCD is a quite strong hypercoagulable condition. Although we do not know how long patients were kept on anticoagulation therapy after the incident VTE event, the high VTE recurrence rate in patients with more severe SCD (>30% at 5 years) suggests that these cases might benefit from indefinite anticoagulation, which is the current suggestion for men who have unprovoked VTE and who also have a 5-year incidence of >30% for recurrent VTE (Kearon et al, 2015 (Kearon et al, , 2016b .
There are limitations to our study. Our case findings required an emergency department visit or inpatient admission and therefore we might have missed healthier SCD patients, although it is likely that most SCD patients had at least 2 or 3 separate admissions with SCD coded over the 23 years of data. We also chose to include only cases with higher likelihood of having sickle cell disease, further lessening our cohort size. However, our cohort number is close to the estimated number of Californians with SCD generated by other investigators (Hassell, 2010; Paulukonis et al, 2014) . The incidence of first-time VTE may be underestimated because of emigration out of California or diagnosis and treatment in the outpatient arena, but this was rare during most of the study period. Nonetheless, the strengths include the large population-based cohort of SCD patients treated across nearly all facilities in California, the long longitudinal follow-up, and the ability to generate a large, matched comparator population, increasing the generalizability of our findings. Additionally, our findings from this observational California, 1991 California, -2013 . SCD patients with severe disease (red line); SCD patients with less severe disease (blue line). Cumulative incidence of recurrent VTE is adjusted for competing risk of death. In the largest cohort study known to date to examine this issue, we show that SCD patients are at an increased risk of VTE even after accounting for frequency of hospitalizations. Women and those with more frequent hospitalizations are at higher risk. VTE in patients with SCD is associated with higher mortality, regardless of the type of VTE. The high rate of VTE recurrence among frequently hospitalized SCD patients warrants consideration of extended anticoagulation and could be studied in a prospective clinical trial.
